PDL BioPharma Inc (PDLI):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9915)
◆英語タイトル:PDL BioPharma Inc (PDLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9915
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to late-stage public and private healthcare companies. PDL provides companies, academic institutions, and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc (PDLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 12
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 13
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 15
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 17
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 18
Licensing Agreements 20
Lee’s Pharma Enters into Licensing Agreement with Noden Pharma 20
PDL BioPharma Enters into Royalty Agreement with AxoGen 21
Equity Offering 22
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 22
Debt Offering 23
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 23
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 24
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 26
PDL BioPharma Inc – Key Competitors 27
PDL BioPharma Inc – Key Employees 28
PDL BioPharma Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 06, 2018: PDL BioPharma reports third quarter 2018 financial results 30
Aug 08, 2018: PDL BioPharma reports second quarter 2018 financial results 32
May 09, 2018: PDL BioPharma Announces First Quarter 2018 Financial Results 34
Mar 08, 2018: PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results 35
Nov 02, 2017: PDL BioPharma Announces Third Quarter 2017 Financial Results 37
Aug 03, 2017: PDL BioPharma Announces Second Quarter 2017 Financial Results 40
May 03, 2017: PDL BioPharma Announces First Quarter 2017 Financial Results 42
Mar 01, 2017: PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results 44
Corporate Communications 46
Jun 22, 2018: Elizabeth O’Farrell Named to PDL BioPharma’s Board of Directors 46
Jun 11, 2018: PDL BioPharma Appoints Shlomo Yanai As Board Director 47
Sep 11, 2017: PDL BioPharma Appoints Dominique Monnet as President 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 12
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 13
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 15
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 17
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 18
Lee's Pharma Enters into Licensing Agreement with Noden Pharma 20
PDL BioPharma Enters into Royalty Agreement with AxoGen 21
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 22
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 23
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 24
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 26
PDL BioPharma Inc, Key Competitors 27
PDL BioPharma Inc, Key Employees 28
PDL BioPharma Inc, Subsidiaries 29

List of Figures
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ PDL BioPharma Inc (PDLI):製薬・医療:M&Aディール及び事業提携情報(PDL BioPharma Inc (PDLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆